Literature DB >> 6596652

Prostaglandin F2 alpha increases responsiveness of pulmonary airways in dogs.

P M O'Byrne, H Aizawa, R A Bethel, K F Chung, J A Nadel, M J Holtzman.   

Abstract

We studied the effect of prostaglandin F2 alpha (PGF2 alpha) on the responsiveness of pulmonary airways in dogs. Airway responsiveness was assessed by determining the bronchoconstrictor response to increasing concentrations of acetylcholine aerosol delivered to the airways. In each of five dogs, we determined responsiveness during treatment with physiologic saline, histamine, or PGF2 alpha aerosols. The doses of histamine and PGF2 alpha were determined by establishing the largest dose of each which could be given to the dog without causing bronchoconstriction (subthreshold doses). We found that airway responsiveness was not significantly different during histamine treatment than after saline, however, responsiveness increased during treatment with PGF2 alpha. In addition, the hyperresponsiveness induced by PGF2 alpha was prevented by pretreatment with the ganglion blocking drug hexamethonium (5 mg/kg given intravenously). The results show that PGF2 alpha specifically increases the responsiveness of pulmonary airways in doses that do not cause bronchoconstriction, and suggest that the hyperresponsiveness involves a neural mechanism such as increased responsiveness of airway sensory nerves.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6596652     DOI: 10.1016/0090-6980(84)90242-9

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  2 in total

1.  Allergic lung responses are increased in prostaglandin H synthase-deficient mice.

Authors:  S H Gavett; S L Madison; P C Chulada; P E Scarborough; W Qu; J E Boyle; H F Tiano; C A Lee; R Langenbach; V L Roggli; D C Zeldin
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

2.  Mast cell activation enhances airway responsiveness to methacholine in the mouse.

Authors:  T R Martin; T Takeishi; H R Katz; K F Austen; J M Drazen; S J Galli
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.